A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

Leukemia - Tập 29 Số 2 - Trang 369-376 - 2015
Helen White1, Liesbet Deprez2, Philippe Corbisier2, Vanessa Jane Hall1, Feng Lin3, Mazoua Stephane2, Stefanie Trapmann2, Anni Aggerholm4, Hajnalka Andrikovics5, Susanna Akiki6, Gisela Barbany7, Nancy Boeckx8, Anthony J. Bench9, Mark Catherwood10, J-M Cayuela11, Sandra Chudleigh12, Tim Clench13, Dolors Colomer14, Filomena Daraio15, Stéphanie Dulucq16, Joanna Farrugia17, Linda Fletcher18, Letizia Foroni19, Rosalind H. Ganderton20, Gareth Gerrard19, Eglė Gineikienė21, Emmanuelle Clappier22, Hakim El Housni23, Barbara Izzo24, Mattias Jansson25, Petra Johnels26, Tomáš Jurček27, Veli Kairisto28, Aytug Kizilors29, Dongwook Kim30, Thoralf Lange31, Thomas Lion32, Kateřina Machová Poláková33, Giovanni Martinelli34, Sarah L. McCarron35, Pauline A. Merle36, Beth Milner37, Gerlinde Mitterbauer‐Hohendanner38, Meital Nagar39, Guillermina Nickless40, Josep Nomdedéu41, Dag André Nymoen42, Elisabeth Oppliger Leibundgut43, Uğur Özbek44, Tadej Pajič45, Roman Pfeifer46, Claude Preudhomme47, Kadri Raudsepp48, Giuliana Romeo49, Tomasz Sacha50, Rodica Tălmaci51, Tasoula Touloumenidou52, Vincent H. J. van der Velden53, Paula Waits54, L Wang55, Elizabeth J. Wilkinson56, Gill Wilson57, Dörte Wren58, Renata Zadro59, Janine M. Ziermann60, Katerina Zoi61, Martin Müller62, Andreas Hochhaus60, Heinz Schimmel2, Nicholas C.P. Cross3, Hendrik Emons2
1National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK
2European Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Geel, Belgium
3Faculty of Medicine, University of Southampton, Southampton, UK
4Department of Haematology, Aarhus University Hospital, Aarhus, Denmark;
5Hungarian National Blood Transfusion Service, Budapest, Hungary
6Regional Genetics Laboratory, Birmingham Women’s NHS Foundation Trust, Birmingham, UK
7Department of Molecular Medicine and Surgery, Clinical Genetics Karolinska Institutet, Stockholm, Sweden
8Department of Laboratory Medicine, UZ Leuven, Belgium
9Molecular Malignancy Laboratory and Haemato-Oncology Diagnostic Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
10Haematology Department, Belfast City Hospital, Belfast, UK
11Haematology Laboratory and EA3518, University Hospital Saint-Louis, AP-HP, University Paris Diderot, Paris, France
12Department of Molecular Haematology, Yorkhill NHS Trust, Glasgow, UK
13Molecular Haematology, Bristol Royal Infirmary, Bristol, UK,
14Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
15Department of Clinical and Biological Science, University of Turin, Turin, Italy
16Laboratoire Hematologie, CHU Bordeaux, Hematopoiese Leucemique et Cibles Therapeutiques, INSERM U1035, Universite Bordeaux, Bordeaux, France,
17Combined Laboratories, Derriford Hospital, Plymouth, UK,
18Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia
19Imperial Molecular Pathology, Centre for Haematology, Imperial College London, London, UK,
20Molecular Pathology, University Hospitals Southampton NHS Foundation Trust, Southampton, UK,
21Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania,
22Laboratory of Molecular Biology and UMR5239, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite, France,
23Medical Genetics Department, Erasme Hospital, Brussels, Belgium,
24Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy
25Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
26Department of Clinical Genetics, University and Regional Laboratories, Lund, Sweden,
27Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic,
28Turku University Hospital, TYKSLAB, Laboratory of Molecular Genetics, Turku, Finland,
29Laboratory for Molecular Haemato-Oncology, Kings College Hospital, London, UK,
30Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea
31Abteilung für Hämatologie und internistische Onkologie, Universität Leipzig, Leipzig, Germany
32Children's Cancer Research Institute/LabDia Labordiagnostik and Medical University, Vienna, Austria,
33Institute of Hematology and Blood Transfusion, Prague, Czech Republic
34Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
35Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland
36Department of Haematology, VU Medical Centre, Amsterdam, the Netherlands
37Department of Medical Genetics, NHS-Grampian, Aberdeen, UK,
38Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
39Laboratory of Hematology, Sheba Medical Center, Tel Hashomer, Israel
40Molecular Oncology Diagnostics Unit, Guy’s Hospital, London, UK,
41Lab Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain,
42Division of Pathology, Rikshospital, Oslo University Hospital, Oslo, Norway,
43Department of Hematology, Molecular Diagnostics Laboratory, University Hospital Bern, Bern, Switzerland,
44Genetics Department, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey,
45Division of Internal Medicine, Department of Haematology, Specialized Haematology Laboratory, University Medical Centre, Ljubljana, Slovenia,
46Department of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany
47Laboratoire d’Hématologie, CHU Lille, Lille, France
48United Laboratories of Tartu University Hospitals, Tartu, Estonia,
49Molecular Haematology Laboratory, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, WA, Australia,
50Hematology Department, Jagiellonian University, Krakow, Poland,
51Hematology Department, Fundeni Clinical Institute, University of Medicine and Pharmacy ‘Carol Davila’, Bucharest, Romania,
52Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
53Department of Immunology, Erasmus MC, Rotterdam, The Netherlands
54Bristol Genetics Laboratory, Southmead Hospital, Bristol, UK
55Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK
56HMDS, Leeds Institute of Oncology, St James's University Hospital, Leeds, UK,
57Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK
58Molecular Diagnostics, The Royal Marsden NHS Foundation Trust, Sutton, UK,
59Department of Laboratory Diagnostics, Clinical Hospital Center, Zagreb University School of Medicine, Zagreb, Croatia,
60Department of Hematology/Oncology, Jena University Hospital, Jena, Germany
61Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece
62III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany

Tóm tắt

Từ khóa


Tài liệu tham khảo

Cross NC . Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 355–365.

Press RD, Kamel-Reid S, Ang D . BCR–ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia. J Mol Diagn 2013; 15: 565–576.

Branford S, Prime J . Chronic myelogenous leukemia: monitoring response to therapy. Curr Hematol Malig Rep 2011; 6: 75–81.

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872–884.

Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE et al. Guidelines for the measurement of BCR–ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 2011; 153: 179–190.

Zhang T, Grenier S, Nwachukwu B, Wei C, Lipton JH, Kamel-Reid S et al. Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn 2007; 9: 421–430.

Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR–ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37.

Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR–ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330–3338.

White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR–ABL mRNA. Blood 2010; 116: e111–e117.

White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A et al. Establishment and validation of analytical reference panels for the standardization of quantitative BCR–ABL1 measurements on the international scale. Clin Chem 2013; 59: 938–948.

Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.

Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957–1963.

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251–2259.

Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260–2270.

Cross NC, White HE, Muller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172–2175.

Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415–423.

Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia 2003; 17: 2474–2486.

Deprez L, Mazoua S, Corbisier P, Trapmann S, Schimmel H, White H et al. The certification of the copy number concentration of solutions of plasmid DNA containing a BCR–ABL b3a2 transcript fragment. Certified reference material: ERM-AD623a, ERM-AD623b, ERM-AD623c, ERM-AD623d, ERM-AD623e ERM-AD623f. Luxembourg: Publications Office of the European Union, 2012; Report number EUR 25248; ISBN 978-92-79-23343-2. 2012.

Joint Committee for Guides in Metrology. Evaluation of measurement data: Guide to expression of uncertainty in measurement (GUM) http://www.bipm.org/utils/common/documents/jcgm/JCGM_100_2008_E.pdf . 2008.

Linsinger TP, Pauwels J, Lamberty A, Schimmel HG, van der Veen AM, Siekmann L et al. Estimating the uncertainty of stability for matrix CRMs. Fresenius J Anal Chem 2001; 370: 183–188.

Muller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T et al. Harmonization of BCR–ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008; 22: 96–102.

van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013–1034.

Jennings LJ, Smith FA, Halling KC, Persons DL, Kamel-Reid S . Molecular Oncology Resource Committee of the College of American P. Design and analytic validation of BCR–ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease. Arch Pathol Lab Med 2012; 136: 33–40.

Thông tin
Thông tin xuất bản

Leukemia

Tập 29 Số 2

369-376

Thông tin tác giả